TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06116851

Intervention type: OTHER
Intervention: MRI scan and laboratory visit
Description: Prostate MRI scan is performed according to the protocol used in earlier studies (PMID 31158230). In addition to the PCa diagnostics, the scan will include abdominal imaging to body composition analysis (visceral and subcutaneous fat and psoas muscle). Baseline blood and urine samples are collected in Turku University Hospital laboratory.

Intervention type: PROCEDURE
Intervention: Prostate biopsies
Description: The visit follows routine outpatient clinic protocol. The results from MRI and laboratory findings are discussed and the potential benefits and harms from prostate biopsies are evaluated. After a mutual decision, prostate biopsies are performed.

Intervention type: PROCEDURE
Intervention: Radical prostatectomy and blood, urine and tissue sampling
Description: Baseline blood and urine samples are collected at the time of surgery. Robotic assisted laparoscopic prostatectomy (RALP) is performed according to routine protocol. Routine diagnostic histopathological procedures will be followed, and study tissue samples are obtained in the department of pathology.

Intervention type: PROCEDURE
Intervention: TURP and blood, urine and tissue sampling
Description: Baseline blood and urine samples are collected the time of surgery. TURP is performed according to normal protocol. Routine diagnostic histopathological procedures will be followed in the department of pathology. Additionally, tissue samples (a total of 10 resection chips) will be collected for study analyses. Due to the study, no additional tissue samples are removed, i.e. study samples are from the tissues removed as clinically indicated.

Intervention type: PROCEDURE
Intervention: Radical cystoprostatectomy and blood, urine and tissue sampling
Description: Baseline blood and urine samples are collected at the time of surgery. Radical cystoprostatectomy is performed according to routine protocol. Routine diagnostic histopathological procedures will be followed, and study tissue samples are obtained in the department of pathology.
Study: NCT04831658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the dose-escalation phase
Description: The study adopts the 3+3 design,The dose planned to be explored is the daily oral dose of the BTK inhibitor abutinib, which is 100 mg, 150 mg and 200 mg, respectively.Orelabrutinib continues to be taken orally until the tumor is relieved for 3 months; PD-1 monoclonal antibody is used by intravenous drip, 21 days as a treatment cycle, and a total of 1 year of observation; formustine is used by intravenous drip for 21 days It is a treatment cycle, a total of 6 cycles of observation; after 2 cycles, the efficacy is evaluated, and adverse reactions are recorded. At the same time, MTX 12mg+Ara-C 50mg+Dex 5mg was injected into the CSF cytology-positive sheath, and intrathecal injection once per treatment cycle, a total of 6 times.
Study: NCT05202405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-221
Description: AD-221 Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-221
Description: AD-221 Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-221A and AD-221B
Description: AD-221A Oral Tablet + AD-221B Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-221A and AD-221B
Description: AD-221A Oral Tablet + AD-221B Oral Tablet
Study: NCT04443829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19CAR T-cells
Description: Infusion with: CD19CAR T-cells
Study: NCT05679310

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol/Essential oils
Description: A dietary supplement containing 10 mg of hydroxytyrosol, synthesised using genetically modified Escherichia coli strains and equal amounts (8.33 μL) of essential oils from oregano vulgaris, sage officinalis and crithmum maritimum.
Study: NCT06052124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Reality Device
Description: AR device will be used to determine where to place SEPS drain

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Reality Device
Description: AR device will be used to determine where to place SEPS drain
Study: NCT06085157

Intervention type: OTHER
Intervention: electronic diary
Description: a smartphone application for self-documentation of drinking pattern
Study: NCT06197126

Intervention type: RADIATION
Intervention: Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .
Description: The chemotherapy regimens included cisplatin (40 mg/m2) or nedaplatin (80 mg/m2) monotherapy or combined with paclitaxel (135 mg/m2) every three weeks during radiotherapy.
Study: NCT05432570

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A - Muscle Relaxants Used
Description: Induction will be achieved with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol, and 0.6 mg/kg rocuronium stored at 4 degrees. After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B - No Muscle Relaxants
Description: Induction will be provided with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol. After ventilation, vocal cords will be seen with a Macintosh laryngoscope, and 2cc of 2% lidocaine will be applied to the vocal cords as a spray with the help of a 5 ml injector. After ventilation, laryngoscopy will be performed with a Macintosh laryngoscope by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
Study: NCT04910217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation
Description: Patients will undergo conventional rehabilitation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation
Description: Patients will undergo conventional rehabilitation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leg/lower body exerciser device intervention.
Description: Patients will undergo leg/lower body exerciser device therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lokomat intervention
Description: Patients will undergo therapy with Lokomat Pro FreeD device intervention.
Study: NCT05203575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Setting plus Weekly Nudge in Cycle 1
Description: The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 1 (first 14 weeks).
Study: NCT04512261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Initial dosage of trial treatment for tucatinib will be given as 300 mg (dispensed as 2 x 150 mg tablets) orally twice a day for Days 1 - 21 of each 3-week cycle during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Initial dosage of trial treatment for pembrolizumab will be given as 200 mg by intravenous infusion every 3 weeks on Day 1 of each 3-week cycle during the treatment period. Pembrolizumab will be administered for a maximum of 35 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Initial dosage of trial treatment for trastuzumab will be given as 8 mg/kg by intravenous (IV) infusion once on Day 1 of Cycle 1, and 6 mg/kg by IV every 3 weeks on Day 1 of each 3-week cycle starting on Cycle 2 during the treatment period.
Study: NCT05480371

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional tracheal suctioning
Description: Group 1 allocated to conventional tracheal suctioning,all patiemts will be followed up until discharge from ICU or death~Tracheal suctioning will be performed following the American Association for Respiratory Care recommendations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation/exsufflation
Description: Group 2 will be allocated to mechanical insufflation-exsufflation which will be performed with the which will be applied 5 times in 5cough cycles in automatic mode, with insufflation and exsufflation pressures of + 40/-40 cmH2O, respectively. The duration of each phase was 3 s, without pause. Hyperoxygenation (100% O2) will be performed for 1 min before applying each technique and a 20 s interval will be allowed between repetitions.
Study: NCT04925323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLOOD SAMPLES
Description: BLOOD SAMPLES

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: surgical tissue samples
Description: unused surgical tissue removed during plastic surgeries
Study: NCT05203575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Setting plus Weekly Nudge in Cycle 1
Description: The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 1 (first 14 weeks).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Setting plus Weekly Nudge in Cycle 1
Description: The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 1 (first 14 weeks).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Setting plus Weekly Nudge in Cycle 1
Description: The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 1 (first 14 weeks).
Study: NCT05463770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-363856, 12.5 mg, 25 mg, and 50 mg tablets. The dose taken at the same time each day, in the evening and in the morning. Multiple tablets may be required to achieve a single dose.
Study: NCT05667129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN-101
Description: Capsule formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule formulation
Study: NCT05993169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Composition optimization visits
Description: Patients who are selected into the body composition optimization (BCO) visits group will attend an extra one hour in-person check-up with Olivia Johnson as part of their regular clinic follow-ups. During their initial BCO visit, patients will complete a hard copy intake form. These BCO visits will take place in the same clinic as the regular visits. These visits will focus on individual concerns and goal-setting. These visits may be changed to online/video follow ups if the patients are finding it difficult to return to main campus that often.
Study: NCT05700838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cough Skill Training - with Variable Practice
Description: Variable practice will involve three targets that reflect a range of cough airflows, including strong, moderate, and weak coughs.
Study: NCT05219695

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Harmonic motion imaging guided focused ultrasound (HMIgFUS)
Description: Harmonic motion imaging guided focused ultrasound (HMIgFUS) is a combined treatment and imaging method, in which focused ultrasound (FUS) is used to thermally ablate tissue and harmonic motion imaging (HMI) is used for FUS guidance and monitoring. FUS applies high intensity focused ultrasound waves at its specified target to heat the tissue over a specified duration, causing cell death at the target area. HMI is an elasticity imaging technique which induces dynamic tissue vibrations at the target for tissue elasticity characterization.~One of the inclusion criteria for this study is that participants must be scheduled for surgical excision of their breast tumor. In this study, HMIgFUS will be applied to anesthetized participants immediately prior to their scheduled surgery. HMI imaging will also be performed immediately prior to and after HMIgFUS application.
Study: NCT05203575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fast-forwarding in Cycle 2
Description: The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 2 (second 14 weeks).
Study: NCT04666298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran sodium
Description: Subcutaneously injected on Day 1, 90 and 270.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran sodium
Description: Subcutaneously injected on Day 1, 90 and 270.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran sodium
Description: Subcutaneously injected on Day 1, 90 and 270.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously injected on Day 1, 90, and 270.
Study: NCT05354934

Intervention type: OTHER
Intervention: quetionnaire
Description: The questionnaire includes the following modules~* Demography and socio-economic conditions~* Screening and modalities of discovery and announcement of HIV infection~* Time and modalities of introduction of antiretroviral drugs after diagnosis~* Knowledge of HIV infection~* The perception of follow-up in the health care service~* Experiences of stigma~* Barriers to accessing care~* Periods of loss of sight and reasons for this~* Perceived health status, mental health (PHQ4), chronic illness, functional limitations~* Addictions~* Social network and support~* Clinical data Date of HIV diagnosis Date of introduction of antiretrovirals CD4 count at diagnosis Viral load at diagnosis Period without follow-up for more than 12 months CD4 nadir Last CD4 count Last viral load Antiretroviral treatment at last consultation Comorbidities Initial hospitalisation Recent hospitalization
Study: NCT04758338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VUMC telehealth services
Description: Participants will access the CTS link (sent to them via email), which will connect them directly to a videoconference and enable them to see and hear the facilitators and other patients in the group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: 25-30 participants will be interviewed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: Participants will be provided educational materials
Study: NCT04593602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Mobilization
Description: Nurse-driven early mobilization activities twice daily

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Mobility Care
Description: Usual mobility care involves following physician orders for mobilization (i.e., bedrest, mobilization to chair with meals, physiotherapy consultation and care) as per local practice.
Study: NCT05044988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10342
Description: HS-10342 tablet once daily from Day 1 to 21 of a 28-day cycle
Study: NCT05203575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Setting plus Weekly Nudge in Cycle 2
Description: The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 2 (second 14 weeks).
Study: NCT05190432

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taxifolin
Description: A naturally occurring polyphenol found in apples, onions and other fruits and bark extracts.
Study: NCT05203575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Setting plus Weekly Nudge in Cycle 2
Description: The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 2 (second 14 weeks).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Setting plus Weekly Nudge in Cycle 2
Description: The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 2 (second 14 weeks).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Setting plus Weekly Nudge in Cycle 2
Description: The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 2 (second 14 weeks).